Planning Strategies’s Alnylam Pharmaceuticals ALNY Stock Holding History

Planning Strategies’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.41K	Buy	+8	New	+$2.41K	﹤0.01%	551

Other funds holding ALNY

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Planning Strategies's ALNY Position: Q2 2026 in Review

Planning Strategies opened a new position in Alnylam Pharmaceuticals (ALNY) in Q2 2026: 8 shares worth $2.41K. The stake represents ﹤0.01% of the portfolio and ranks #551 among its holdings.

733 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

Planning Strategies held 8 shares of Alnylam Pharmaceuticals worth $2.41K as of Q2 2026.
Alnylam Pharmaceuticals was a new Planning Strategies position in Q2 2026.
Alnylam Pharmaceuticals made up ﹤0.01% of Planning Strategies's portfolio in Q2 2026, its #551 holding.
733 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Planning Strategies's 13F filing for Q2 2026, filed 27 Jul 2026.